1-deoxynojirimycin has been researched along with Lupus Erythematosus, Systemic in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Butters, T; Deepak, S; Hall, CJ; Isenberg, DA; Jury, EC; Magee, AI; McDonald, G; Miguel, L | 1 |
1 other study(ies) available for 1-deoxynojirimycin and Lupus Erythematosus, Systemic
Article | Year |
---|---|
Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients.
Topics: 1-Deoxynojirimycin; Adult; Aged; Antigens, CD; B-Lymphocytes; CD4-Positive T-Lymphocytes; Female; Flow Cytometry; G(M1) Ganglioside; Gene Expression Regulation; Glycosphingolipids; Homeostasis; Humans; Lactosylceramides; Leukocytes, Mononuclear; Liver X Receptors; Lupus Erythematosus, Systemic; Lymphocyte Activation; Male; Membrane Microdomains; Middle Aged; Orphan Nuclear Receptors; Signal Transduction; Time Factors; Trihexosylceramides | 2014 |